Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paying For Personalized Medicine: Medicare CED Approach Advised

This article was originally published in The Gray Sheet

Executive Summary

If CMS proceeds with a national coverage determination on diagnostics for patient-specific drug therapy, it should consider a Coverage with Evidence Development approach, the Personalized Medicine Coalition suggests in Sept. 26 comments to the agency
Advertisement

Related Content

Dear Daschle: HHS Advisors Draft Personalized Medicine Priorities For 2009
Dear Daschle: HHS Advisors Draft Personalized Medicine Priorities For 2009
Dear Daschle: HHS Advisors Draft Personalized Medicine Priorities For 2009
Is Data Adequate To Support Warfarin Dosing Test Coverage? Comments Vary
CMS Floats Topics For Possible National Coverage Determinations
CMS Floats Topics For Possible National Coverage Determinations
Advertisement
UsernamePublicRestriction

Register

MT026676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel